Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients

Abstract

Objectives: To assess the influence of stage at breast cancer diagnosis, tumour biology, and treatment on survival in contemporary times of better (neo-)adjuvant systemic therapy.

Design: Prospective nationwide population based study.

Setting: Nationwide Netherlands Cancer Registry.

Participants: Female patients with primary breast cancer diagnosed between 1999 and 2012 (n=173,797), subdivided into two time cohorts on the basis of breast cancer diagnosis: 1999-2005 (n=80,228) and 2006-12 (n=93,569).

Main outcome measures: Relative survival was compared between the two cohorts. Influence of traditional prognostic factors on overall mortality was analysed with Cox regression for each cohort separately.

Results: Compared with 1999-2005, patients from 2006-12 had smaller (≤ T1 65% (n=60,570) v 60% (n=48,031); P<0.001), more often lymph node negative (N0 68% (n=63,544) v 65% (n=52,238); P<0.001) tumours, but they received more chemotherapy, hormonal therapy, and targeted therapy (neo-adjuvant/adjuvant systemic therapy 60% (n=56,402) v 53% (n=42,185); P<0.001). Median follow-up was 9.8 years for 1999-2005 and 3.9 years for 2006-12. The relative five year survival rate in 2006-12 was 96%, improved in all tumour and nodal stages compared with 1999-2005, and 100% in tumours ≤ 1 cm. In multivariable analyses adjusted for age and tumour type, overall mortality was decreased by surgery (especially breast conserving), radiotherapy, and systemic therapies. Mortality increased with progressing tumour size in both cohorts (2006-12 T1c v T1a: hazard ratio 1.54, 95% confidence interval 1.33 to 1.78), but without a significant difference in invasive breast cancers until 1 cm (2006-12 T1b v T1a: hazard ratio 1.04, 0.88 to 1.22), and independently with progressing number of positive lymph nodes (2006-12 N1 v N0: 1.25, 1.17 to 1.32).

Conclusions: Tumour stage at diagnosis of breast cancer still influences overall survival significantly in the current era of effective systemic therapy. Diagnosis of breast cancer at an early tumour stage remains vital.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

© Saadatmand et al 2015.

Figures

Fig 1 Tumour stage specific relative survival of breast cancer patients in Netherlands Cancer Registry diagnosed as having breast cancer in 1999-2005 (top) and 2006-12 (bottom). Relative survival was defined as observed survival divided by expected survival of corresponding general population, matched by sex, age, and year of diagnosis. Tis=ductal carcinoma in situ; T1a=≤0.5 cm (including micro-invasion); T1b=>0.5 cm and ≤1 cm; T1c=>1 cm and ≤2 cm; T2=>2 cm and ≤5 cm; T3=>5 cm; T4=any size with direct extension to chest wall and/or skin

Fig 2 Nodal stage specific relative survival of breast cancer patients in Netherlands Cancer Registry diagnosed as having breast cancer in 1999-2005 (top) and 2006-12 (bottom). Relative survival was defined as observed survival divided by expected survival of corresponding general population, matched by sex, age, and year of diagnosis. N0=no pathologically assessed regional lymph nodes with metastasis/isolated tumour cells; N1=metastasis in 1-3 regional lymph nodes; N2=metastasis in 4-9 regional lymph nodes; N3=metastasis in ≥10 regional lymph nodes